Stephen Gehlbach to Risk Factors
This is a "connection" page, showing publications Stephen Gehlbach has written about Risk Factors.
Connection Strength
0.394
-
FitzGerald G, Compston JE, Chapurlat RD, Pfeilschifter J, Cooper C, Hosmer DW, Adachi JD, Anderson FA, D?ez-P?rez A, Greenspan SL, Netelenbos JC, Nieves JW, Rossini M, Watts NB, Hooven FH, LaCroix AZ, March L, Roux C, Saag KG, Siris ES, Silverman S, Gehlbach SH. Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW). J Clin Endocrinol Metab. 2014 Mar; 99(3):817-26.
Score: 0.056
-
Gehlbach S, Hooven FH, Wyman A, Diez-Perez A, Adachi JD, Luo X, Bushmakin AG, Anderson FA. Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). PLoS One. 2013; 8(12):e82840.
Score: 0.056
-
Gehlbach S, Saag KG, Adachi JD, Hooven FH, Flahive J, Boonen S, Chapurlat RD, Compston JE, Cooper C, D?ez-Perez A, Greenspan SL, LaCroix AZ, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Sambrook PN, Silverman S, Siris ES, Watts NB, Lindsay R. Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res. 2012 Mar; 27(3):645-53.
Score: 0.050
-
Sambrook PN, Flahive J, Hooven FH, Boonen S, Chapurlat R, Lindsay R, Nguyen TV, D?ez-Perez A, Pfeilschifter J, Greenspan SL, Hosmer D, Netelenbos JC, Adachi JD, Watts NB, Cooper C, Roux C, Rossini M, Siris ES, Silverman S, Saag KG, Compston JE, LaCroix A, Gehlbach S. Predicting fractures in an international cohort using risk factor algorithms without BMD. J Bone Miner Res. 2011 Nov; 26(11):2770-7.
Score: 0.048
-
D?ez-P?rez A, Hooven FH, Adachi JD, Adami S, Anderson FA, Boonen S, Chapurlat R, Compston JE, Cooper C, Delmas P, Greenspan SL, Lacroix AZ, Lindsay R, Netelenbos JC, Pfeilschifter J, Roux C, Saag KG, Sambrook P, Silverman S, Siris ES, Watts NB, Nika G, Gehlbach SH. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2011 Sep; 49(3):493-8.
Score: 0.047
-
Gehlbach SH, Avrunin JS, Puleo E, Spaeth R. Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int. 2007 Jun; 18(6):805-10.
Score: 0.035
-
Compston JE, Wyman A, FitzGerald G, Adachi JD, Chapurlat RD, Cooper C, D?ez-P?rez A, Gehlbach SH, Greenspan SL, Hooven FH, LaCroix AZ, March L, Netelenbos JC, Nieves JW, Pfeilschifter J, Rossini M, Roux C, Saag KG, Siris ES, Silverman S, Watts NB, Anderson FA. Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res. 2016 07; 31(7):1466-72.
Score: 0.017
-
Compston JE, Flahive J, Hosmer DW, Watts NB, Siris ES, Silverman S, Saag KG, Roux C, Rossini M, Pfeilschifter J, Nieves JW, Netelenbos JC, March L, LaCroix AZ, Hooven FH, Greenspan SL, Gehlbach SH, D?ez-P?rez A, Cooper C, Chapurlat RD, Boonen S, Anderson FA, Adami S, Adachi JD. Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). J Bone Miner Res. 2014 Feb; 29(2):487-93.
Score: 0.014
-
D?ez-P?rez A, Adachi JD, Adami S, Anderson FA, Boonen S, Chapurlat R, Compston JE, Cooper C, Gehlbach SH, Greenspan SL, Hooven FH, LaCroix AZ, Nieves JW, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Saag KG, Silverman S, Siris ES, Wyman A, Rushton-Smith SK, Watts NB. Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res. 2014 Jan; 29(1):260-7.
Score: 0.014
-
FitzGerald G, Boonen S, Compston JE, Pfeilschifter J, LaCroix AZ, Hosmer DW, Hooven FH, Gehlbach SH. Differing risk profiles for individual fracture sites: evidence from the Global Longitudinal Study of Osteoporosis in Women (GLOW). J Bone Miner Res. 2012 Sep; 27(9):1907-15.
Score: 0.013
-
Dennison EM, Compston JE, Flahive J, Siris ES, Gehlbach SH, Adachi JD, Boonen S, Chapurlat R, D?ez-P?rez A, Anderson FA, Hooven FH, LaCroix AZ, Lindsay R, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Saag KG, Sambrook P, Silverman S, Watts NB, Greenspan SL, Premaor M, Cooper C. Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2012 Jun; 50(6):1288-93.
Score: 0.012
-
Greenspan SL, Wyman A, Hooven FH, Adami S, Gehlbach S, Anderson FA, Boone S, Lacroix AZ, Lindsay R, Netelenbos JC, Pfeilschifter J, Silverman S, Siris ES, Watts NB. Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatr Soc. 2012 Mar; 60(3):455-61.
Score: 0.012
-
Compston JE, Watts NB, Chapurlat R, Cooper C, Boonen S, Greenspan S, Pfeilschifter J, Silverman S, D?ez-P?rez A, Lindsay R, Saag KG, Netelenbos JC, Gehlbach S, Hooven FH, Flahive J, Adachi JD, Rossini M, Lacroix AZ, Roux C, Sambrook PN, Siris ES. Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med. 2011 Nov; 124(11):1043-50.
Score: 0.012
-
Hooven F, Gehlbach SH, Pekow P, Bertone E, Benjamin E. Follow-up treatment for osteoporosis after fracture. Osteoporos Int. 2005 Mar; 16(3):296-301.
Score: 0.007